NCT01730248 - A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 18, 2012

Primary Completion Date

September 28, 2017

Study Completion Date

September 28, 2017

Conditions

Myelofibrosis

Interventions

DRUG

INC424

5 mg tablets administered orally twice daily

DRUG

BKM120

10 mg and 50 mg hard gelatin capsules administered orally once daily

Trial Locations (15)

3000

Novartis Investigative Site, Melbourne

4029

Novartis Investigative Site, Herston

13353

Novartis Investigative Site, Berlin

18057

Novartis Investigative Site, Rostock

21100

Novartis Investigative Site, Varese

28041

Novartis Investigative Site, Madrid

50134

Novartis Investigative Site, Florence

75010

Novartis Investigative Site, Paris

91120

Novartis Investigative Site, Jerusalem

169608

Novartis Investigative Site, Singapore

5265601

Novartis Investigative Site, Ramat Gan

A-1090

Novartis Investigative Site, Vienna

B15 2WB

Novartis Investigative Site, Edgbaston

NW1 2BU

Novartis Investigative Site, London

SE1 9RT

Novartis Investigative Site, London